Editor’s Note
**Editor’s Note:** Apex Medical (4186) highlights its advancements in precision testing and regenerative medicine at Bio Asia 2026, focusing on food safety, drug identification, and extracellular vesicle technology to foster global bio-sector collaboration.
Apex Medical (4186) is showcasing its technological strengths in precision testing, food safety, drug identification, and regenerative medicine at the 2026 Bio Asia Exhibition. The company’s four core exhibition themes are “Food Safety Testing, Drug Testing, Monoclonal/Polyclonal Antibody Technology, and Extracellular Vesicle Application Technology.” Through in-depth exchanges with domestic and international partners in biotechnology, healthcare, testing, and related industries, Apex Medical aims to expand its global collaboration footprint and drive the next wave of operational growth.
Apex Medical stated that its exhibition strategy is centered on the B2B market. Leveraging the Bio Asia platform, the company seeks to deepen exchanges with partners including food manufacturers, medical institutions, biotech firms, government agencies, testing laboratories, and international distributors. The goal is to drive product adoption and technical collaboration, increase market penetration, and expand overseas market presence.
In food safety testing, Apex Medical has established a comprehensive platform covering food additives, veterinary drug residues, mycotoxins, and various other food safety parameters. It offers rapid, accurate, and highly efficient testing solutions to help food businesses, catering services, schools, and other entities build complete quality management and risk control mechanisms that comply with increasingly stringent food safety regulations.
Drug testing serves as one of Apex Medical’s key growth engines. The company has built a complete one-stop drug testing platform widely applicable in judicial, police, corporate, transportation, and occupational safety management sectors. It provides efficient and credible testing services to meet the growing demands of both government and enterprises.
In the regenerative medicine field, Apex Medical is showcasing its achievements in monoclonal and polyclonal cell culture technology, offering cell process services that meet quality management standards. These services assist academic research institutions, biotech companies, and medical facilities in establishing stable, high-quality cell application platforms, while continuing to expand into the precision medicine and cell therapy markets to enhance overall competitiveness in regenerative medicine.
Extracellular vesicle (EV) application technology is another highlight of this exhibition. Due to their crucial role in intercellular communication, EVs have recently attracted significant attention in regenerative medicine, precision medicine, aesthetic medicine, and new drug development markets. Apex Medical continues to invest in EV-related R&D, aiming to accelerate the commercialization and clinical application of EV-based products through technical cooperation and strategic alliances, thereby opening up broader international markets.
